Vertex Pharmaceuticals’ (VRTX) “Sector Perform” Rating Reaffirmed at Royal Bank of Canada
Royal Bank of Canada reaffirmed their sector perform rating on shares of Vertex Pharmaceuticals (NASDAQ:VRTX – Free Report) in a report released on Thursday morning, Benzinga reports. They currently have a $431.00 price objective on the pharmaceutical company’s stock. VRTX has been the subject of a number of other research reports. Wells Fargo & Company […]
23 Sep 05:56 · The Markets Daily